

# Coactosin-like 1 integrates signaling critical for shear-dependent thrombus formation in mouse platelets

Inga Scheller,<sup>1,2</sup> Simon Stritt,<sup>1,2,\*</sup> Sarah Beck,<sup>1,2</sup> Bing Peng,<sup>3</sup> Irina Pleines,<sup>1,2</sup> Katrin G. Heinze,<sup>2</sup> Attila Braun,<sup>1,2</sup> Oliver Otto,<sup>4</sup> Robert Ahrends,<sup>3</sup> Albert Sickmann,<sup>3</sup> Markus Bender,<sup>1,2</sup> and Bernhard Nieswandt<sup>1,2</sup>

<sup>1</sup>Institute of Experimental Biomedicine I, University Hospital, University of Würzburg, Würzburg; <sup>2</sup>Rudolf Virchow Center, University of Würzburg, Würzburg; <sup>3</sup>Leibniz-Institut für Analytische Wissenschaften - ISAS - e.V., Lipidomics, Dortmund and <sup>4</sup>Center for Innovation Competence - Humoral Immune Reactions in Cardiovascular Diseases, Biomechanics, University of Greifswald, Greifswald, Germany.

\*Current affiliation: Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.



Haematologica 2020  
Volume 105(6):1667-1676

## ABSTRACT

Platelet aggregate formation is a multistep process involving receptor-mediated, as well as biomechanical, signaling cascades, which are highly dependent on actin dynamics. We have previously shown that actin depolymerizing factor (ADF)/n-cofilin and Twinfilin 2a, members of the ADF homology (ADF-H) protein family, have distinct roles in platelet formation and function. Coactosin-like 1 (Cotl1) is another ADF-H protein that binds actin and was also shown to enhance biosynthesis of pro-inflammatory leukotrienes (LT) in granulocytes. Here, we generated mice lacking Cotl1 in the megakaryocyte lineage (*Cotl1*<sup>-/-</sup>) to investigate its role in platelet production and function. Absence of Cotl1 had no impact on platelet counts, platelet activation or cytoskeletal reorganization under static conditions *in vitro*. In contrast, Cotl1 deficiency markedly affected platelet aggregate formation on collagen and adhesion to immobilized von Willebrand factor at high shear rates *in vitro*, pointing to an impaired function of the platelet mechanoreceptor glycoprotein (GP) Ib. Furthermore, *Cotl1*<sup>-/-</sup> platelets exhibited increased deformability at high shear rates, indicating that the GPIb defect may be linked to altered biomechanical properties of the deficient cells. In addition, we found that Cotl1 deficiency markedly affected platelet LT biosynthesis. Strikingly, exogenous LT addition restored defective aggregate formation of *Cotl1*<sup>-/-</sup> platelets at high shear *in vitro*, indicating a critical role of platelet-derived LT in thrombus formation. *In vivo*, Cotl1 deficiency translated into prolonged tail bleeding times and protection from occlusive arterial thrombus formation. Together, our results show that Cotl1 in platelets is an integrator of biomechanical and LT signaling in hemostasis and thrombosis.

## Introduction

Platelets are small anucleate cells that are essential for hemostasis and maintenance of vascular integrity, but are also implicated in thrombosis resulting in ischemia and infarction under pathological conditions.<sup>1</sup> The classic, simplified model of platelet-dependent arterial thrombus formation comprises sequential steps, involving platelet deceleration on the injured vessel wall *via* interaction of the platelet mechanoreceptor glycoprotein (GP) Ib with von Willebrand factor (vWF) immobilized on the injured vessel wall. This is followed by cellular activation *via* the collagen receptor GPVI and G protein-coupled receptors (GPCR) stimulated by soluble agonists such as ADP, thromboxane A<sub>2</sub> (TxA<sub>2</sub>) or thrombin. The final common pathway of these activatory events is the functional upregulation of integrins, which mediate firm platelet adhesion and aggregation.

## Correspondence:

BERNHARD NIESWANDT  
bernhard.nieswandt@virchow.uni-wuerzburg.de

Received: April 29, 2019.

Accepted: September 26, 2019.

Pre-published: October 3, 2019.

doi:10.3324/haematol.2019.225516

Check the online version for the most updated information on this article, online supplements, and information on authorship & disclosures: [www.haematologica.org/content/105/6/1667](http://www.haematologica.org/content/105/6/1667)

©2020 Ferrata Storti Foundation

Material published in *Haematologica* is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions:

<https://creativecommons.org/licenses/by-nc/4.0/legalcode>. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions: <https://creativecommons.org/licenses/by-nc/4.0/legalcode>, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.



Critical determinants of thrombus formation are the locally prevailing rheological conditions. With increasing shear rate, e.g. during the development of stenosis, platelet adhesion and aggregate formation become increasingly dependent on GPIb-vWF interactions. At sites of very high, pathological shear rates and disturbed flow, occlusive arterial thrombus formation can be mediated predominantly by the GPIb-vWF interaction, does not involve visible platelet shape change or activation, and may thus be mediated, at least in part, by the biomechanical interaction of platelets.<sup>2</sup> In accordance with this, it was shown that vWF-mediated pulling at the GPIb $\alpha$  receptor under shear induces the unfolding of a juxtamembrane mechanosensitive domain, which might contribute to platelet mechanosensing under dynamic conditions and GPIb-induced intracellular signaling.<sup>3</sup> Thus, it appears that platelet-mediated thrombus formation *in vivo* involves both agonist receptor and biomechanical signaling, the interplay of which is still poorly understood.

Platelets are produced by megakaryocytes (MK) in the bone marrow (BM) through a cytoskeleton-driven process. The critical role of the actin cytoskeleton for platelet production and function is illustrated by the association of mutations in genes encoding proteins that are involved in actin cytoskeletal organization, such as Diaphanous Related Formin 1 (*DIAPH1*),<sup>4</sup> filamin A (*FLNA*),<sup>5</sup> Wiskott Aldrich syndrom protein (*WASP*),<sup>6</sup> actinin 1 (*ACTN1*),<sup>7</sup> or tropomyosin 4 (*TPM4*)<sup>8</sup> with platelet disorders in humans and mice. In circulating platelets, the actin cytoskeleton is essential to maintain cell morphology and to exert key functions upon activation, such as granule release, as well as the formation of filopodia and lamellipodia.<sup>9</sup> However, the complex protein network orchestrating actin dynamics in platelets is not fully understood.

The ADF homology domain (ADF-H) is one of the best-characterized actin binding motifs. The ADF-H protein family comprises twinfilin (Twf), ADF/n-cofilin, Abp1/drebrin, and coactosin-like 1 (Cot1/CLP). We have previously shown that Twf2a and ADF/n-cofilin play distinct, critical roles in platelet formation and function.<sup>10,11</sup> Although sharing less than 20% sequence identity with the other ADF-H family members, Cot1 is structurally highly homologous, suggesting a similar role for cytoskeletal dynamics.<sup>12</sup> Indeed, Cot1 binds F-actin, but does not interact with actin monomers.<sup>13</sup> Furthermore, Cot1 was shown to prevent n-cofilin-mediated depolymerization of actin filaments, thereby promoting lamellipodia formation at the immune synapse.<sup>14</sup> Besides its interaction with F-actin, Cot1 is implicated in the biosynthesis of leukotrienes (LT),<sup>15</sup> lipid-derived pro-inflammatory mediators involved in a variety of inflammatory processes such as allergy or asthma. Cot1 was shown to interact with 5-lipoxygenase (5-LO), a key enzyme in LT biosynthesis that catalyzes two of the initial steps, namely the oxygenation of arachidonic acid (AA) to 5-HPETE and the subsequent dehydration into the epoxide LTA4.<sup>15-17</sup> Platelet-stored LT have been shown to contribute to inflammatory responses, e.g. during lung inflammation.<sup>18</sup> However, the mechanism underlying this contribution, as well as the precise role of LT for platelet function, have not been defined.

Here, we generated conditional knockout mice lacking Cot1 in the MK lineage. We found that Cot1 is critically required for stable platelet thrombus formation under con-

ditions of shear flow *in vitro* and *in vivo* by modulating the function of the mechanoreceptor GPIb, as well as platelet LT biosynthesis.

## Methods

### Animals

*Cot1*<sup>-/-</sup> mice were generated by injection of embryonic stem cell clone *Cot1*<sup>tm1a(EUCOMM)Hmgui</sup> into C57Bl/6 blastocysts. Germline transmission was confirmed by backcrossing of the chimeric mice with C57Bl/6 mice. *Cot1*<sup>+/-</sup> mice were intercrossed with mice carrying Flp recombinase to generate *Cot1*<sup>fl/fl</sup> mice, which were intercrossed with mice carrying Cre recombinase under control of the platelet factor 4 (P4) promoter to generate mice lacking Cot1 specifically in MK and platelets.<sup>19</sup> For all experiments, 12- to 16-week old *Cot1*<sup>fl/fl;P4Cre</sup> and *Cot1*<sup>fl/fl</sup> littermate controls, maintained on a C57Bl/6 background, were used. All mice were derived from the following breeding strategy: *Cot1*<sup>fl/fl;P4Cre</sup> X *Cot1*<sup>fl/fl</sup>.

### Animal studies

Animal studies were approved by the district government of Lower Franconia (AZ15\_14; Bezirksregierung Unterfranken).

Further details of reagents and experimental procedures are given in the *Online Supplementary Appendix*.


## Results

### Cot1 deficiency does not affect platelet function under static conditions

*Cot1*<sup>fl/fl;P4Cre</sup> mice (hereon referred to as *Cot1*<sup>-/-</sup>) were viable and born in the expected Mendelian ratios. The absence of Cot1 in platelets was confirmed by western blotting (*Online Supplementary Figure S1A*). Cot1 deficiency did not affect either peripheral platelet count, size or ultrastructure (Figure 1A-C) nor the expression of prominent platelet surface receptors (*Online Supplementary Table S1*). This is in contrast to deficiency in the ADF-H protein family members Twf2a<sup>11</sup> or n-cofilin,<sup>10</sup> which results in thrombocytopenia in mice. Thus, *Cot1*<sup>-/-</sup> mice represent the first knockout mouse model of an ADF-H family member with apparently normal platelet biogenesis.

A common feature of ADF-H family members is their involvement in cytoskeletal dynamics. Consistently, n-cofilin deficiency resulted in impaired stimulus-dependent F-actin assembly, whereas Twf2a-deficient mice displayed increased actin dynamics.<sup>10,11</sup> According to previous studies, n-cofilin and Cot1 are highly abundant in both human and mouse platelets,<sup>20,21</sup> while Twf2 levels are slightly lower. The results for Twf1 and drebrin, which was not listed in the mouse dataset, suggest that they are expressed at a lower level. Importantly, both datasets indicate that the expression of ADF-H proteins is similar in human and mouse platelets.

We determined expression levels of the ADF-H members Twf1/2a and n-cofilin by western blotting, but could not detect differences in total expression levels of either protein between WT and *Cot1*<sup>-/-</sup> platelets (Figure 1D and E). Strikingly, we observed a strong (2-fold) increase in expression of the (inactive) phosphorylated form of n-cofilin (Ser3) in *Cot1*<sup>-/-</sup> platelets (\*\**P*<0.001) (Figure 1E and F). Next, we analyzed the localization of Cot1 in resting and spread platelets (*Online Supplementary Figure S1B and C*). In line with previous observations,<sup>22</sup> we



**Figure 1. Cot1 is not essential for platelet formation and function under static conditions *in vitro*.** (A and B) Platelet count (A) and size (B) were determined with an automated cell analyzer (SciVet). (C) Visualization of platelet size and structure using transmission electron microscopy (n=4). Scale bar, 2  $\mu$ m. (D-F) Platelets were left untreated, lysed, and processed for immunoblotting. Total twinfilin (D), phosphorylated n-cofilin and total n-cofilin (E) were probed with the respective antibodies and analyzed by densitometry (F). GAPDH served as loading control. Values are mean $\pm$ standard deviation (SD) (n=3). (G) Images of the platelet cytoskeleton ultrastructure on poly-L-lysine. (Left) WT sample. (Right) *Cot1*<sup>-/-</sup> sample. 0: intact, 1: partially disrupted, 2: strongly disrupted F-actin structures. Scale bar, 1  $\mu$ m. At least 158 platelets per genotype were analyzed.

observed a cytoplasmic localization which partially overlapped with that of F-actin and tubulin. When visualizing the F-actin ultrastructure in resting platelets by transmission electron microscopy (TEM),<sup>23</sup> we observed that the actin scaffold was disrupted in a significant proportion of *Cot1*-deficient platelets compared to the WT: (1) partially disrupted: *Cot1*<sup>-/-</sup> 17.1% versus WT 4.9%, \*\* $P > 0.01$ ; (2) strongly disrupted: *Cot1*<sup>-/-</sup> 8.2% vs. WT 3% (Figure 1G). However, we could not detect changes in resting F-actin levels or agonist-induced F-actin polymerization in *Cot1*<sup>-/-</sup> platelets (Online Supplementary Figure S2A and B). In addition, although *Cot1* was recently described as a regulator of T-cell spreading at the immune synapse,<sup>14</sup> *Cot1* deficiency in platelets did not affect their ability to spread on fibrinogen (Online Supplementary Figure S2C), as shown by normal morphology and distribution of F-actin and tubulin in the spread platelets (Online Supplementary Figure S2D and E).

Together, these results indicated that *Cot1* is not essential for platelet production or platelet actin remodeling.

### **Cot1 is required for platelet aggregate formation under flow conditions**

We next studied the effect of *Cot1* deficiency on agonist-induced platelet activation. Flow cytometry was used to determine activation of the major platelet integrin  $\alpha$ IIb $\beta$ 3 as well as degranulation (P-selectin exposure) in response to a panel of standard agonists (Online Supplementary Figure S3A and B). In contrast to the hyper-reactivity of *Twf2a*-deficient platelets,<sup>11</sup> *Cot1*<sup>-/-</sup> platelets displayed unaltered responses to agonists acting on both GPCR (thrombin, ADP, TxA<sub>2</sub> analog U46619) and (hem)ITAM signaling (collagen-related peptide (CRP), convulxin, rhodocytin) (Online Supplementary Figure S3A and B). Furthermore, washed *Cot1*<sup>-/-</sup> platelets showed unaltered aggregation upon stimulation with thrombin, U46619, collagen and CRP as compared to the control (Online Supplementary Figure S4A). Similar results were obtained when using platelet-rich plasma (PRP) instead of washed platelets (Online Supplementary Figure S4B). These results demonstrated that *Cot1* is not required for platelet

activation and aggregation responses under static conditions *in vitro*.

In sharp contrast, however, *Cot11* deficiency markedly affected platelet aggregation and thrombus formation under shear flow conditions *in vitro*. We used a flow adhesion assay where the perfusion of whole anticoagulated *WT* blood over a collagen-coated surface leads to rapid platelet adhesion, activation and three-dimensional aggregate formation. While aggregate formation at low shear ( $150\text{ s}^{-1}$ ) was comparable between *Cot11*<sup>-/-</sup> and *WT* samples, we observed significantly reduced platelet adhesion, surface coverage and thrombus volume in blood from *Cot11*<sup>-/-</sup> animals at medium and high shear rates ( $1\,000\text{ s}^{-1}$ , \* $P < 0.05$ ;  $3\,000\text{ s}^{-1}$ , \*\* $P < 0.01$ ) (Figure 2A-C and *Online Supplementary Figure S5*). Strikingly, thrombus volume and platelet surface coverage were also significantly reduced in blood from *Cot11*<sup>-/-</sup> mice when the flow adhesion assay was carried out in the presence of coagulation (*Online Supplementary Figure S6*).

Platelet adhesion and aggregate formation under medium and high shear rates is dependent on the interaction between the mechanoreceptor GPIb and immobilized vWF.<sup>24</sup> To investigate a possible involvement of *Cot11* in GPIb-mediated tethering/adhesion, we perfused blood from *WT* and *Cot11*<sup>-/-</sup> animals over a vWF-coated surface at high shear ( $3,000\text{ s}^{-1}$ ). The velocity of individual rolling *Cot11*<sup>-/-</sup> platelets on immobilized vWF was comparable to the *WT* (Figure 2E, right); however, the number of adherent *Cot11*<sup>-/-</sup> platelets was significantly reduced (\*\* $P < 0.01$ ) (Figure 2D and E). Our results thus indicated that *Cot11* is required to ensure GPIb function during platelet adhesion and aggregate formation under conditions of high shear.

Growing experimental evidence suggests that signaling induced by the GPIb-vWF interaction involves mechanotransduction and transmission of forces to the actin cytoskeleton.<sup>25,26</sup> Therefore, to assess the impact of *Cot11* deficiency on platelet biomechanical properties more generally, we subjected *Cot11*<sup>-/-</sup> platelets to the recently described real-time deformability cytometry (RT-DC),<sup>27</sup> a method for continuous mechanical characterization of cells which are deformed by shear forces in a microfluidics chamber (Figure 2F). Strikingly, we found a significantly increased deformability of *Cot11*<sup>-/-</sup> platelets (\* $P < 0.05$ ) as compared to *WT* (Figure 2G and H, right). Importantly, we could exclude the possibility that the increased deformability was due to an increased platelet size; by contrast, the measured size of *Cot11*<sup>-/-</sup> platelets in this assay was even slightly decreased as compared to the control (Figure 2H, left). Together, these results indicate that *Cot11* supports GPIb function and thus the formation of stable platelet aggregates under shear conditions, and that this function may, in part, be mediated by the modulation of platelet biomechanical properties.

### **Cot11 regulates leukotriene biosynthesis in platelets**

Leukotrienes are pro-inflammatory lipid mediators mainly produced by immune competent cells such as leukocytes, e.g. mast cells, eosinophils, neutrophils, monocytes and basophils, and are implicated in a variety of inflammatory responses. Interestingly, besides its function as an actin-regulatory protein, *Cot11* was shown to bind and modulate the activity of the enzyme 5-lipoxygenase (5-LO).<sup>15,17,28</sup> 5-LO catalyzes the two initial steps of LT biosynthesis: (1) the oxygenation of AA to 5-HPETE; and (2) the subsequent dehydration into leukotriene A<sub>4</sub> (LTA<sub>4</sub>)

which is then further converted to LTB<sub>4</sub> (*Online Supplementary Figure S7*).<sup>29,30</sup> Besides serving as substrate for LT biosynthesis, AA is converted to thromboxanes (TxA<sub>2</sub>/B<sub>2</sub>), prostacyclin (PGI<sub>2</sub>), and prostaglandins (PGE<sub>2</sub>/F<sub>2</sub>) by cyclo-oxygenases in platelets (*Online Supplementary Figure S4*).<sup>31,32</sup>


To investigate the effect of *Cot11* deficiency on LT production in platelets, we assessed the release of 5,12-diHETE and LTB<sub>4</sub> in the supernatant of washed CRP- or thrombin-stimulated platelets. Strikingly, the secretion of both lipid mediators was significantly reduced in *Cot11*<sup>-/-</sup> platelets upon CRP activation as compared to *WT* controls and a similar tendency was observed for thrombin-stimulated platelets (\* $P < 0.05$ ) (Figure 3A). Of note, the total AA amount was comparable to *WT* platelets, demonstrating that the abundance of this initial metabolite was not affected by *Cot11* deficiency (Figure 3A, left). To assess whether AA was consumed by other pathways, we analyzed TxB<sub>2</sub> levels by ELISA. Strikingly, we found significantly increased TxB<sub>2</sub> release in thrombin-stimulated and, to a lesser extent, CRP-stimulated *Cot11*<sup>-/-</sup> platelets compared to the control (\* $P < 0.05$ ), indicating that the excess of available AA in *Cot11*<sup>-/-</sup> platelets was consumed by an upregulation of prostaglandin biosynthesis (*Online Supplementary Figure S8*).

To assess whether, indeed, *Cot11* directly influences 5-LO activity, lysates of CRP- or thrombin-stimulated platelets were probed for active 5-LO (S663 phosphorylation) by western blotting (Figure 3B). Of note, basal levels of active 5-LO were comparable between *Cot11*<sup>-/-</sup> and *WT* platelets. Strikingly, while activation induced pronounced S663 phosphorylation in *WT* platelets, this process was significantly reduced in *Cot11*<sup>-/-</sup> platelets (thrombin: \* $P < 0.05$ ; CRP: \*\* $P < 0.01$ ) (Figure 3B and C). Together, these results demonstrated that *Cot11* directly influences 5-LO activity, ultimately resulting in reduced biosynthesis and, subsequently, release of LT from *Cot11*<sup>-/-</sup> platelets.

### **Defective shear-dependent thrombus formation in Cot11-deficient mice is rescued by exogenous addition of leukotriene B<sub>4</sub>**

We next investigated whether the reduced release of lipid mediators in *Cot11*<sup>-/-</sup> mice contributed to defective platelet aggregate formation of *Cot11*<sup>-/-</sup> platelets under flow. We decided to focus on LTB<sub>4</sub>, one of the end products of the LT biosynthesis pathway downstream of LTA<sub>4</sub>, which was shown to stimulate neutrophil chemotaxis<sup>33</sup> and activation.<sup>34</sup> First, we tested whether LTB<sub>4</sub> was able to directly induce platelet activation. As LTB<sub>4</sub> was described to induce neutrophil aggregation and degranulation at concentrations of  $0.1\text{ }\mu\text{M}$ <sup>35,36</sup> and leukocyte aggregation, chemotaxis and chemokinesis at a subnanomolar range of  $0.39\text{ nM}$ ,<sup>35</sup> we used concentrations of  $0.025\text{--}250\text{ nM}$  LTB<sub>4</sub> (Cayman Chemicals) in our assays. None of the tested LTB<sub>4</sub> concentrations induced platelet activation under static conditions *in vitro* (*Online Supplementary Figures S9A* and *S10A*). Likewise, LTB<sub>4</sub> addition did not further enhance integrin  $\alpha\text{IIb}\beta\text{3}$  activation, degranulation or aggregation of *WT* or *Cot11*<sup>-/-</sup> platelets (*Online Supplementary Figures S9B* and *S10B*).


Using the *in vitro* flow adhesion assay (Figure 2A-C), we next investigated the effect of LTB<sub>4</sub> on platelet aggregate formation under flow. Adding concentrations of  $2.5\text{ nM}$  or higher interfered with aggregate formation ( $1,700\text{ s}^{-1}$ ) in *WT* blood, whereas lower concentrations had no effect



**Figure 2. Cot11 is required for thrombus formation and stability at high shear.** (A-C) Assessment of platelet adhesion (A and B) and aggregate formation (A and C) on Horm collagen (70 μg mL<sup>-1</sup>) under flow (150-3 000 s<sup>-1</sup>) in heparinized whole blood of WT and Cot11<sup>-/-</sup> mice. Values are mean±standard deviation (SD) (n=12). Scale bar, 50 μm. (D and E) Heparinized whole blood of WT and Cot11<sup>-/-</sup> mice was perfused over a von Willebrand factor (vWF)-coated cover slip for 4 minutes (min) at a shear rate of 3,000 s<sup>-1</sup>. (D) Representative phase contrast images taken at the end of the perfusion time and (E) analysis of the number of adherent platelets per mm<sup>2</sup> ±SD (left), as well as the rolling velocity calculated from the distance a platelet covered per minute in μm ±SD (right) was performed. Images were acquired with a Zeiss Axiovert 200 inverted microscope (40x/0.6 oil objective). Images are representative of at least 12 animals per group. Scale bar, 50 μm. Unpaired Student t-test: \*\*P<0.01; \*P<0.05. (F-H) Real-time deformability cytometry (RT-DC),<sup>27</sup> a method for continuous mechanical characterization of cells which are deformed by deceleration at the stagnation point of fast extensional flow. (F) Scheme depicting the principle of real-time deformability cytometry (RT-DC). (G) Representative dot plots showing the relative deformation, as well as the (H) the size of washed WT and Cot11<sup>-/-</sup> platelets. Values are mean±SD (n=3). \*P<0.1; \*\*P<0.01. A.U. : arbitrary units.

(Online Supplementary Figure S11A and B). Strikingly, pre-incubation with 0.25 nM LTB<sub>4</sub> could fully restore aggregate formation of *Cott1*<sup>-/-</sup> platelets to WT levels (Figure 4A and B), indicating that the defect observed in untreated *Cott1*<sup>-/-</sup> samples was caused by impaired platelet-derived LTB<sub>4</sub> production. To investigate whether LTB<sub>4</sub> has a more general function in this context, we analyzed two additional knockout mouse lines with a described defect in the flow adhesion assay: *Grb2*<sup>fl/fl;P4<sup>Cre</sup></sup> (*Grb2*<sup>-/-</sup>) mice have normal platelet counts but the platelets display a selective GPVI/ITAM activation defect.<sup>37</sup> *RhoA*<sup>fl/fl;P4<sup>Cre</sup></sup> (*RhoA*<sup>-/-</sup>) mice are thrombocytopenic and deficient platelets display

impaired G protein coupled receptor (GPCR) signaling.<sup>38</sup> Notably, the addition of LTB<sub>4</sub> to anticoagulated blood from *Grb2*<sup>-/-</sup> mice resulted in moderately increased platelet surface coverage ( $P=0.06$ ) as compared to untreated samples, but could not restore aggregate formation to WT levels (Online Supplementary Figure S12). Furthermore, LTB<sub>4</sub> addition had no effect on aggregate formation in platelet-count adjusted blood of *RhoA*<sup>-/-</sup> mice (Online Supplementary Figure S13). Together, these findings demonstrated that addition of LTB<sub>4</sub> cannot compensate for defective platelet aggregate formation under flow in the presence of prominent platelet activation/secretion defects. At the same



**Figure 3. *Cott1* is a regulator of leukotriene biosynthesis in platelets.** (A) For lipid mediator analysis platelets were either left untreated or stimulated with CRP [5 μg mL<sup>-1</sup>] or thrombin [0.01 U mL<sup>-1</sup>] for 5 minutes (min). Subsequently, samples were spun down, pellet and supernatant were separately shock-frozen in liquid nitrogen. Lipid abundance was assessed using liquid crystal mass spectrometry. Values are mean±standard deviation (SD) (n=15). (B and C) Platelets were either left untreated or stimulated with CRP [5 μg mL<sup>-1</sup>] or thrombin [0.01 U mL<sup>-1</sup>] for 5 min, lysed, and processed for immunoblotting. Total 5-LO, phospho-5-LO (S663) and GAPDH (B) were probed with the respective antibodies and analyzed by densitometry (C). Values are mean±SD (n=4).


time, our results emphasize that reduced LTB<sub>4</sub> production in *Cot11*<sup>-/-</sup> platelets, which display no obvious activation defect *per se*, significantly contributed to the impaired aggregate formation in the presence of shear.

### Cot11 modulates thrombosis and hemostasis


To investigate whether the impaired shear-dependent aggregate formation translated into a phenotype *in vivo*, we subjected *Cot11*<sup>-/-</sup> mice to an experimental model of arterial thrombosis. Since it is well documented that collagen is a main driver of thrombus formation in bigger vessels, particularly in models of mechanical injury, we chose a model where the abdominal aorta is mechanically injured. This procedure triggers rapid platelet adhesion to the injured vessel wall, followed by the development of a large occlusive thrombus associated with dynamic changes in both shear and biomechanical forces acting on adhering platelets in the growing thrombus. Strikingly, *Cot11*<sup>-/-</sup> mice were profoundly protected from occlusive thrombus formation in this model (Figure 5A and B). In

WT mice, irreversible vessel occlusion was observed within 7 minutes (min) after injury (mean occlusion time 3.37±0.72 min). In sharp contrast, while a progressive reduction in blood flow occurred during the first minutes after injury in *Cot11*<sup>-/-</sup> mice, indicative of beginning thrombus formation and increasing stenosis, blood flow afterwards normalized and 9 of 11 mice displayed normal blood flow through the injured vessel at the end of the observation period (30 min) (\*\**P*<0.001). These results demonstrated that Cot11 is essential for occlusive arterial thrombus formation *in vivo*.

To assess the hemostatic function of *Cot11*<sup>-/-</sup> platelets, we performed a tail bleeding assay. Notably, while tail bleeding times were overall significantly increased in *Cot11*<sup>-/-</sup> mice (7.8±12.2 min in *Cot11*<sup>-/-</sup> mice vs. 3.3±1.8 min in WT; \**P*<0.05) the hemostatic defect was rather mild given the profound protection in the arterial thrombosis model (Figure 5C), indicating that Cot11 may be particularly important in settings of pathological thrombus formation.



**Figure 4. Defective shear-dependent thrombus formation in *Cot11*-deficient mice can be rescued by exogenous addition of leukotriene B<sub>4</sub>.** (A-C) Assessment of platelet adhesion (A and B) and aggregate formation in heparinized blood (A and C) on Horm collagen (70 μg mL<sup>-1</sup>) under flow (1700 s<sup>-1</sup>). WT and *Cot11*<sup>-/-</sup> samples were either left untreated or were pre-incubated for 5 minutes (min) with LTB<sub>4</sub> [0.25 nM]. Images are representatives of at least 12 mice per group. Values are mean±standard deviation. Scale bar, 50 μm. \**P*<0.1; \*\**P*<0.01.



**Figure 5. Cot1 modulates thrombosis and hemostasis.** (A and B) **Intravital thrombosis model.** (A) Representative graph of blood flow of one WT and one Cot1<sup>-/-</sup> mouse after mechanical injury of the abdominal aorta. (B) Occlusion times after mechanical injury of the abdominal aorta. Data are mean±standard deviation of at least eight mice per group. (C) Tail bleeding times in WT and Cot1<sup>-/-</sup> mice (filter paper method). Each symbol represents one individual. Unpaired Student t-test: \*\*\**P*<0.001; \**P*<0.05.

## Discussion

Here, we demonstrate for the first time that the small ADF-H-domain-containing actin-binding protein Cot1 has entirely different functions compared to the other protein family members ADF/n-cofilin and Twf, at least in platelets. Cot1 deficiency neither had an impact on thrombopoiesis or platelet function under static conditions *in vitro*, nor did it obviously affect actin reorganization. Strikingly, we could reveal a critical role of Cot1 for stable thrombus formation under conditions of shear *in vitro* and *in vivo*. Our results point to two distinct and so far undescribed roles of Cot1 in this process. On the one hand, the F-actin binding function of the protein is required for proper GPIb function and possibly shear-induced biomechanical signaling. On the other hand, the 5-LO enzyme-modulating function of Cot1 promotes the biosynthesis of LT, which positively modulate thrombus formation.

The crucial role of actin cytoskeletal rearrangements for platelet formation and reactivity has been demonstrated in a number of studies.<sup>5,7,8,10,11,39</sup> While we have previously shown that lack of either Twf2a or n-cofilin in the MK lineage results in thrombocytopenia and distinct platelet function defects,<sup>10,11</sup> deficiency of Cot1 did not affect circulating platelet counts. This may be explained by the distinct actin-binding properties and biological activities of each ADF-H member, which can be attributed to their different domain structure.<sup>12</sup> Hence, n-cofilin deficiency decreased stimulus-dependent F-actin assembly, whereas on the contrary, Twf2a-deficient mice displayed enhanced actin dynamics.<sup>10,11</sup> Notably, we observed strongly elevated levels of phosphorylated (inactive) n-cofilin in Cot1-deficient platelets. This finding was unexpected given that, in T cells, Cot1 was shown to be required for spreading at the immune synapse by protecting F-actin from n-cofilin-mediated severing,<sup>14</sup> which would suggest enhanced rather than reduced n-cofilin activity in the absence of Cot1. We still cannot explain this apparent discrepancy but can exclude the possibility that it was caused by a direct compensation by another ADF-H protein member since expression of Twf1/2a and n-cofilin were unaltered in Cot1<sup>-/-</sup> compared to WT platelets.

Over the past few years, greater attention has been given to the critical influence of blood rheology and its dynamical changes on platelet adhesion and thrombus growth, including the relevance of mechanotransduction-based signaling *in vivo*. Best studied in this context is the platelet mechanoreceptor GPIb which plays a pivotal role for platelet adhesion, as well as thrombus formation at high shear.<sup>24</sup> We observed that the reduced aggregate formation of Cot1<sup>-/-</sup> platelets on collagen under flow *in vitro* was most pronounced at high shear rates, where GPIb becomes increasingly important. Consistently, GPIb-mediated adhesion of Cot1<sup>-/-</sup> platelets to vWF was significantly reduced. Together, this indicates an involvement of Cot1 in basic GPIb-mediated platelet responses.

The cytoplasmic domain of the GPIb $\alpha$  subunit is tightly linked to the actin cytoskeleton. This interaction is critical for the correct localization of GPIb in the plasma membrane<sup>40</sup> and probably also enables mechanotransduction upon binding of GPIb to its ligand vWF at high shear rates. To study whether the actin-regulating function of Cot1 in platelets may be specifically critical under shear conditions, we used a novel, quite general, approach to characterize platelet biomechanical properties by assessing their shear-induced deformability using RT-DC.<sup>27</sup> This assay has the advantage that, in contrast to other experimental approaches, the biomechanical function of a high cell number can be readily analyzed, and this increases the reliability of the results. Despite not detecting defects in actin assembly under static conditions, strikingly, we observed higher deformability of Cot1-deficient platelets in RT-DC measurements. Our results, therefore, clearly show that biomechanical properties are significantly altered in Cot1-deficient platelets, which may have a substantial influence on their function *in vivo*, possibly also affecting signaling of the mechanoreceptor GPIb.

Besides its interaction with F-actin, Cot1 is a binding partner of 5-LO, the key enzyme in LT biosynthesis,<sup>15</sup> which is expressed in immune competent cells and platelets. LT are a group of inflammatory mediators derived from AA. Upon activation, intracellular Ca<sup>2+</sup> levels increase, free AA is liberated from membrane phospholipids by phospholipases, and 5-LO is activated, leading to



the generation of intermediate LTA<sub>4</sub> and subsequently the production of the different LT types (*Online Supplementary Figure S7*).<sup>35</sup> Besides the cysteinyl (cysLT) LT (LTC<sub>4</sub>, LTD<sub>4</sub>, LTE<sub>4</sub>), these also include LTB<sub>4</sub>, which stimulates neutrophil chemotaxis,<sup>35</sup> enhances neutrophil-endothelial interactions,<sup>41</sup> and stimulates neutrophil activation, leading to degranulation and the release of mediators, enzymes, and superoxides.<sup>34</sup> LTB<sub>4</sub> can also act on other cell types, e.g. by increasing interleukin (IL)-6 production by human monocytes.<sup>42</sup> Platelet-derived LT were shown to contribute to inflammatory responses, e.g. during acute inflammation *via* activation of leukocytes,<sup>18,43</sup> but only a few very early *in vitro* studies indicated an impact of LT directly on platelet aggregation.<sup>18,43</sup>

A recent comprehensive analysis of the platelet lipidome by Peng *et al.* revealed that the AA/5-LO/LT pathway is significantly induced by platelet activation.<sup>44</sup> Therefore, to directly assess whether lack of Cot11 down-regulates 5-LO activity and hence LT biosynthesis, we characterized platelet lipid mediator levels using mass spectrometry.<sup>44</sup> Our data confirm previous findings from other cell types that Cot11 positively regulates 5-LO,<sup>17</sup> as lack of Cot11 induced a shift from LT to prostaglandin biosynthesis downstream from AA, leading to reduced levels of LTA<sub>4</sub> and LTB<sub>4</sub>, but higher levels of TxB<sub>2</sub> in the knock-out platelets. Interestingly, CRP (but not thrombin) was able to induce significant LTB<sub>4</sub> release in *WT* platelets. This is in line with findings by Peng *et al.* who observed that CRP, but not thrombin alone, was able to induce significant changes in the platelet lipidome.<sup>44</sup> Thus, our detailed study further shows that the AA/LTB<sub>4</sub> pathway is induced by GPVI/ITAM rather than GPCR signaling in platelets.

Strikingly, our results indicate that exogenous addition of LTB<sub>4</sub> could fully rescue the defective aggregate formation of Cot11-deficient platelets on collagen under flow *in vitro* (Figure 4). While this finding indicates that the exogenous addition of LT can compensate for the GPIb function defect in Cot11-deficient platelets, we cannot exclude that

GPIb signaling itself is involved in LT biosynthesis. Notably, exogenous addition of LTB<sub>4</sub> did not restore aggregate formation of RhoA- or Grb2-deficient platelets, which *per se* display significant activation/ secretion defects. These results show that LTB<sub>4</sub> secretion is required to fine-tune platelet function under flow rather than being a strong positive regulator of thrombus formation. However, LTB<sub>4</sub> addition could moderately increase aggregate formation of Grb2-deficient platelets, which display defective GPVI/ITAM signaling. This further suggests that LTB<sub>4</sub> is particularly relevant for platelet aggregate formation induced through the GPIb/GPVI/ITAM axis. It will be important to dissect the detailed signaling mechanisms leading to LT generation, as well as the precise role of LT and their signaling pathways for platelet thrombus formation *in vivo* in future studies.

Taken together, our study reveals that Cot11 modulates biomechanical properties of platelets and acts as a signaling integrator in thrombotic processes. Given that both GPIb and LT represent potential therapeutic targets for a number of thrombo-inflammatory and autoimmune diseases, our findings may contribute to a better understanding of the molecular pathways orchestrating these processes.

#### Acknowledgments

We thank Stefanie Hartmann for excellent technical assistance and the microscopy platform of the Bioimaging Center (Rudolf Virchow Centre) for providing technical infrastructure and support. This work was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) (NI 556/11-2 to BN and project number 374031971 – TRR 240). MB is supported by an Emmy Noether grant of the DFG (BE5084/3-1). OO gratefully acknowledges support from the German Ministry of Education and Research (ZIK grant to OO under grant agreement 03Z22CN11). RA received further support from the Federal Ministry of Education and Research (BMBF) in the German Network Bioinformatics Infrastructure (de.NBI) initiative (grants n. 031L0108A and n. 031 A 534B).

#### References

- Ruggeri ZM. Platelets in atherothrombosis. *Nat Med.* 2002;8(11):1227-1234.
- Jackson SP, Nesbitt WS, Kulkarni S. Signaling events underlying thrombus formation. *J Thromb Haemost.* 2003;1(7):1602-1612.
- Zhang W, Deng W, Zhou L, et al. Identification of a juxtamembrane mechanosensitive domain in the platelet mechanosensor glycoprotein Ib-IX complex. *Blood.* 2015;125(3):562-569.
- Stritt S, Nurden P, Turro E, et al. A gain-of-function variant in *DIAPH1* causes dominant macrothrombocytopenia and hearing loss. *Blood.* 2016;127(23):2903-2914.
- Nurden P, Debili N, Coupry I, et al. Thrombocytopenia resulting from mutations in filamin A can be expressed as an isolated syndrome. *Blood.* 2011;118(22):5928-5937.
- Thrasher AJ, Burns SO. WASP: a key immunological multitasker. *Nat Rev Immunol.* 2010;10(3):182-192.
- Kunishima S, Okuno Y, Yoshida K, et al. ACTN1 mutations cause congenital macrothrombocytopenia. *Am J Hum Genet.* 2013;92(3):431-438.
- Pleines I, Woods J, Chappaz S, et al. Mutations in tropomyosin 4 underlie a rare form of human macrothrombocytopenia. *J Clin Invest.* 2017;127(3):814-829.
- Hartwig JH. Mechanisms of actin rearrangements mediating platelet activation. *J Cell Biol.* 1992;118(6):1421-1442.
- Bender M, Eckly A, Hartwig JH, et al. ADF/n-cofilin-dependent actin turnover determines platelet formation and sizing. *Blood.* 2010;116(10):1767-1775.
- Stritt S, Beck S, Becker IC, et al. Twinfilin 2a regulates platelet reactivity and turnover in mice. *Blood.* 2017;130(15):1746-1756.
- Hellman M, Paavilainen VO, Naumanen P, Lappalainen P, Annala A, Permi P. Solution structure of coactosin reveals structural homology to ADF/cofilin family proteins. *FEBS Lett.* 2004;576(1-2):91-96.
- Provost P, Doucet J, Stock A, Gerisch G, Samuelsson B, Rådmark O. Coactosin-like protein, a human F-actin-binding protein: critical role of lysine-75. *Biochem J.* 2001;359(Pt 2):255-263.
- Kim J, Shapiro MJ, Bamidele AO, et al. Coactosin-Like 1 Antagonizes Cofilin to Promote Lamellipodial Protrusion at the Immune Synapse. *PLoS One.* 2014;9(1):e85090.
- Provost P, Doucet J, Hammarberg T, Gerisch G, Samuelsson B, Rådmark O. 5-Lipoxygenase Interacts with Coactosin-like Protein. *J Biol Chem.* 2001;276(19):16520-16527.
- Esser J, Rakonjac M, Hofmann B, et al. Coactosin-like protein functions as a stabilizing chaperone for 5-lipoxygenase: role of tryptophan 102. *Biochem J.* 2010;425(1):265-274.
- Rakonjac M, Fischer L, Provost P, et al. Coactosin-like protein supports 5-lipoxygenase enzyme activity and up-regulates leukotriene A(4) production. *Proc Natl Acad Sci U S A.* 2006;103(35):13150-13155.
- Evangelista V, Celardo A, Dell'Elba G, et al. Platelet contribution to leukotriene production in inflammation: *in vivo* evidence in the rabbit. *Thromb Haemost.* 1999;81(3):442-448.
- Tiedt R, Schomber T, Hao-Shen H, Skoda RC. *em>P4-Cre</em> transgenic mice*

- allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo. *Blood*. 2007;109(4):1503-1506.
20. Burkhart JM, Vaudel M, Gambaryan S, et al. The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. *Blood*. 2012;120(15):e73-82.
  21. Zeiler M, Moser M, Mann M. Copy number analysis of the murine platelet proteome spanning the complete abundance range. *Mol Cell Proteomics*. 2014;13(12):3435-3445.
  22. Provost P, Doucet J, Stock A, Gerisch G, Samuelsson B, Rådmark O. Coactosin-like protein, a human F-actin-binding protein: critical role of lysine-75. *Biochem J*. 2001;359(Pt 2):255-263.
  23. Spindler M, van Eeuwijk JMM, Schurr Y, et al. ADAP deficiency impairs megakaryocyte polarization with ectopic proplatelet release and causes microthrombocytopenia. *Blood*. 2018;132(6):635-646.
  24. Turitto VT, Weiss HJ, Baumgartner HR. The effect of shear rate on platelet interaction with subendothelium exposed to citrated human blood. *Microvasc Res*. 1980;19(3):352-365.
  25. Feghhi S, Munday AD, Tooley WW, et al. Glycoprotein Ib-IX-V Complex Transmits Cytoskeletal Forces That Enhance Platelet Adhesion. *Biophys J*. 2016;111(3):601-608.
  26. Hansen CE, Qiu Y, McCarty OJT, Lam WA. Platelet Mechanotransduction. *Ann Rev Biomed Eng*. 2018;20(1):253-275.
  27. Otto O, Rosendahl P, Mietke A, et al. Real-time deformability cytometry: on-the-fly cell mechanical phenotyping. *Nat Met*. 2015;12(3):199-202.
  28. Provost P, Samuelsson B, Rådmark O. Interaction of 5-lipoxygenase with cellular proteins. *Proc Natl Acad Sci U S A*. 1999;96(5):1881-1885.
  29. Samuelsson B, Dahlen S, Lindgren J, Rouzer C, Serhan C. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. *Science*. 1987;237(4819):1171-1176.
  30. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. *Science*. 1983;220(4597):568-575.
  31. Hamberg M, Samuelsson B. Detection and Isolation of an Endoperoxide Intermediate in Prostaglandin Biosynthesis. *Proc Natl Acad Sci U S A*. 1973;70(3):899-903.
  32. Nugteren DH, Hazelhof E. Isolation and properties of intermediates in prostaglandin biosynthesis. *Biochim Biophys Acta Lipids Lipid Metab*. 1973;326(3):448-461.
  33. Palmer RMJ, Stepney RJ, Higgs GA, Eakins KE. Chemokinetic activity of arachidonic acid lipoxygenase products on leucocytes of different species. *Prostaglandins*. 1980;20(2):411-418.
  34. Sha'Afi RI, Naccache PH, Molski TFP, Borgeat P, Goetzl EJ. Cellular regulatory role of leukotriene B4: Its effects on cation homeostasis in rabbit neutrophils. *J Cell Physiol*. 1981;108(3):401-408.
  35. Ford-Hutchinson AW. Leukotriene B4 in inflammation. *Crit Rev Immunol*. 1990;10(1):1-12.
  36. McMillan RM, Foster SJ. Leukotriene B4 and inflammatory disease. *Agents Actions*. 1988;24(1):114-119.
  37. Dutting S, Vogtle T, Morowski M, et al. Growth factor receptor-bound protein 2 contributes to (hem)immunoreceptor tyrosine-based activation motif-mediated signaling in platelets. *Circ Res*. 2014;114(3):444-453.
  38. Pleines I, Hagedorn I, Gupta S, et al. Megakaryocyte-specific RhoA deficiency causes macrothrombocytopenia and defective platelet activation in hemostasis and thrombosis. *Blood*. 2012;119(4):1054-1063.
  39. Bender M, Stritt S, Nurden P, et al. Megakaryocyte-specific Profilin1-deficiency alters microtubule stability and causes a Wiskott-Aldrich syndrome-like platelet defect. *Nat Commun*. 2014;5(4746).
  40. Nakamura F, Pudas R, Heikkinen O, et al. The structure of the GPIb-filamin A complex. *Blood*. 2006;107(5):1925.
  41. Hoover RL, Karnovsky MJ, Austen KF, Corey EJ, Lewis RA. Leukotriene B4 action on endothelium mediates augmented neutrophil/endothelial adhesion. *Proc Natl Acad Sci U S A*. 1984;81(7):2191-2193.
  42. Brach MA, De Vos S, Arnold C, Gräß H-J, Mertelsmann R, Herrmann F. Leukotriene B4 transcriptionally activates interleukin-6 expression involving NK- $\kappa$ B and NF-IL6. *European J Immunol*. 1992;22(10):2705-2711.
  43. Macclouf J, de Lacroix BF, Borgeat P. Stimulation of leukotriene biosynthesis in human blood leukocytes by platelet-derived 12-hydroperoxy-icosatetraenoic acid. *Proc Natl Acad Sci U S A*. 1982;79(19):6042-6046.
  44. Peng B, Geue S, Coman C, et al. Identification of key lipids critical for platelet activation by comprehensive analysis of the platelet lipidome. *Blood*. 2018;81(7):e1-e12.